LianBio, Inc. announced the first patient has been dosed in the Phase III EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy.
[LianBio, Inc.]
Sorry, but the selected Zotpress account can't be found.
